J 2018

Post-Translational Modifications and Diastolic Calcium Leak Associated to the Novel RyR2-D3638A Mutation Lead to CPVT in Patient-Specific hiPSC-Derived Cardiomyocytes

AĆIMOVIĆ, Ivana, Marwan M. REFAAT, Adrien MOREAU, Anton SALYKIN, Steve REIKEN et. al.

Basic information

Original name

Post-Translational Modifications and Diastolic Calcium Leak Associated to the Novel RyR2-D3638A Mutation Lead to CPVT in Patient-Specific hiPSC-Derived Cardiomyocytes

Authors

AĆIMOVIĆ, Ivana (688 Serbia, belonging to the institution), Marwan M. REFAAT (422 Lebanon), Adrien MOREAU (250 France), Anton SALYKIN (643 Russian Federation, belonging to the institution), Steve REIKEN (840 United States of America), Yvonne SLEIMAN (250 France), Monia SOUIDI (250 France), Jan PŘIBYL (203 Czech Republic, belonging to the institution), Andrey V. KAJAVA (643 Russian Federation), Sylvian RICHARD (250 France), Jonathan T. LU (840 United States of America), Philippe CHEVALIER (250 France), Petr SKLÁDAL (203 Czech Republic, belonging to the institution), Petr DVOŘÁK (203 Czech Republic, belonging to the institution), Vladimír ROTREKL (203 Czech Republic, belonging to the institution), Andrew R. MARKS (840 United States of America), Melvin M. SCHEINMAN (840 United States of America), Alain LACAMPAGNE (250 France, guarantor) and Albano C. MELI (250 France)

Edition

JOURNAL OF CLINICAL MEDICINE, BASEL, MDPI, 2018, 2077-0383

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.688

RIV identification code

RIV/00216224:14110/18:00101651

Organization unit

Faculty of Medicine

UT WoS

000451311900046

Keywords in English

ryanodine receptor; CPVT; hiPSC-derived cardiomyocytes; calcium; beta-adrenergic receptor blockade; flecainide; post-translational modifications

Tags

International impact, Reviewed
Změněno: 7/3/2019 16:32, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

Background: Sarcoplasmic reticulum Ca2+ leak and post-translational modifications under stress have been implicated in catecholaminergic polymorphic ventricular tachycardia (CPVT), a highly lethal inherited arrhythmogenic disorder. Human induced pluripotent stem cells (hiPSCs) offer a unique opportunity for disease modeling. Objective: The aims were to obtain functional hiPSC-derived cardiomyocytes from a CPVT patient harboring a novel ryanodine receptor (RyR2) mutation and model the syndrome, drug responses and investigate the molecular mechanisms associated to the CPVT syndrome. Methods: Patient-specific cardiomyocytes were generated from a young athletic female diagnosed with CPVT. The contractile, intracellular Ca2+ handling and electrophysiological properties as well as the RyR2 macromolecular remodeling were studied. Results: Exercise stress electrocardiography revealed polymorphic ventricular tachycardia when treated with metoprolol and marked improvement with flecainide alone. We found abnormal stress-induced contractile and electrophysiological properties associated with sarcoplasmic reticulum Ca2+ leak in CPVT hiPSC-derived cardiomyocytes. We found inadequate response to metoprolol and a potent response of flecainide. Stabilizing RyR2 with a Rycal compound prevents those abnormalities specifically in CPVT hiPSC-derived cardiomyocytes. The RyR2-D3638A mutation is located in the conformational change inducing-central core domain and leads to RyR2 macromolecular remodeling including depletion of PP2A and Calstabin2. Conclusion: We identified a novel RyR2-D3638A mutation causing 3D conformational defects and aberrant biophysical properties associated to RyR2 macromolecular complex post-translational remodeling. The molecular remodeling is for the first time revealed using patient-specific hiPSC-derived cardiomyocytes which may explain the CPVT proband's resistance. Our study promotes hiPSC-derived cardiomyocytes as a suitable model for disease modeling, testing new therapeutic compounds, personalized medicine and deciphering underlying molecular mechanisms.

Links

GBP302/12/G157, research and development project
Name: Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii
Investor: Czech Science Foundation
LM2015043, research and development project
Name: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
2SGA2744, interní kód MU
Name: CARDIOSTEM (Acronym: CARDIOSTEM)
Investor: South-Moravian Region, Incoming grants